PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 324.00
Bid: 322.00
Ask: 325.00
Change: -13.00 (-3.86%)
Spread: 3.00 (0.932%)
Open: 321.00
High: 326.00
Low: 311.00
Prev. Close: 337.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directors' Share Dealing

15 Aug 2017 10:30

RNS Number : 0249O
Hutchison China Meditech Limited
15 August 2017
 

 

 

Directors' Share Dealing

 

London: Tuesday, August 15, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notifications that:-

 

(a) Mr Simon To, Executive Director and Chairman, through Dynamic Drive Limited, a person closely associated ("PCA") with Mr To, purchased a total of 3,188 American Depositary Shares of the Company ("ADSs", each representing one half of one ordinary share of US$1.00 each in the capital of Chi-Med) on August 14, 2017 at a price of US$24.47 per ADS. Dynamic Drive Limited is controlled by the trustee of Dynamic Drive Trust (the "DDT") which has been established for the benefit of Mr To's family members, of which Mr To is the settlor; and

 

(b) Ms Edith Shih, Non-executive Director and Company Secretary, purchased a total of 5,001 ADSs at an average price of US$25.67 per ADS on August 10 and 11, 2017.

 

Following the above purchases, (i) Mr To is interested in 113,589 ADSs (in DDT and Wencheng Trust of which his family members are the beneficiaries) and 180,000 Ordinary Shares (including the holding of 78,000 Ordinary Shares in DDT of which his family members are the beneficiaries), representing in aggregate approximately 0.39% of the current issued share capital of Chi-Med; and (ii) Ms Shih is interested in 90,664 ADSs and 70,000 Ordinary Shares, representing approximately 0.19% of the current issued share capital of Chi-Med.

 

The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

 

(a) Dynamic Drive Limited

 

1

Details of the person discharging managerial responsibilities/person closely associated

 

a)

 

Name

 

Dynamic Drive Limited

2

Reason for the notification

 

a)

 

Position/status

 

Person closely associated with Mr Simon To, Executive Director and Chairman. Dynamic Drive Limited is controlled by the trustee of Dynamic Drive Trust which has been established for the benefit of Mr To's family members, of which Mr To is the settlor.

 

 

b)

 

Initial notification/Amendment

 

 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Hutchison China MediTech Limited

 

 

b)

 

LEI

 

2138006X34YDQ6OBYE79

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Identification code

 

ADS each representing one half of one Ordinary Share of US$1.00

 

ADS ISIN: US44842L1035

 

 

b)

 

Nature of the transaction

 

Acquisition of 3,188 ADSs in the name of Dynamic Drive Limited which holds the ADSs for a family trust (Dynamic Drive Trust) of which Mr To is the settlor on August 14, 2017 at a price of US$24.47 per ADS.

 

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

US$24.47

3,188

 

 

 

d)

 

Aggregated information

- Aggregated volume

- Price

 

 

N/A

 

 

 

e)

 

Date of the transaction

 

2017-08-14

 

 

f)

 

Place of the transaction

 

Nasdaq Stock Market

 

 

 

(b) Ms Edith Shih

 

1

Details of the person discharging managerial responsibilities/person closely associated

 

a)

 

Name

 

Ms Edith Shih

 

2

Reason for the notification

 

a)

 

Position/status

 

Non-executive Director and Company Secretary

 

 

b)

 

Initial notification/Amendment

 

 

Initial notification

 

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Hutchison China MediTech Limited

 

b)

 

 

LEI

 

2138006X34YDQ6OBYE79

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Identification code

 

 

ADS each representing one half of one Ordinary Share of US$1.00

 

ADS ISIN: US44842L1035

 

 

b)

 

Nature of the transaction

 

Acquisition of 5,001 ADSs on August 10 and 11, 2017 at an average price of US$25.67 per ADS.

 

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

US$25.60

1,904

US$25.58

96

US$25.70

1,900

US$25.69

100

US$25.75

900

US$25.74

100

US$25.40

1

 

 

 

d)

 

Aggregated information

- Aggregated volume

- Price

 

 

Aggregated volume: 5,001 ADSs

Price information: US$25.67

 

e)

 

Date of the transaction

 

2017-08-10 - acquisition of 5,000 ADSs

2017-08-11 - acquisition of one ADS

 

 

f)

 

Place of the transaction

 

Nasdaq Stock Market

 

 

 

About Chi-Med

 

Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

 

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited ("CK Hutchison") (SEHK: 0001). For more information, please visit: www.chi-med.com.

 

 

CONTACTS

 

Investor Enquiries

Mark Lee,

SVP Corporate Finance & Development

+852 2121 8200

U.K. & International Media Enquiries

Anthony Carlisle, Citigate Dewe Rogerson

+44 7973 611 888 (Mobile)

anthony.carlisle@cdrconsultancy.co.uk

U.S. Based Media Enquiries

Brad Miles, BMC Communications

+1 (917) 570 7340 (Mobile)

bmiles@bmccommunications.com

Susan Duffy, BMC Communications

+1 (917) 499 8887 (Mobile)

sduffy@bmccommunications.com

Investor Relations

Matt Beck, The Trout Group

+1 (917) 415 1750 (Mobile)

mbeck@troutgroup.com

David Dible, Citigate Dewe Rogerson

+44 7967 566 919 (Mobile)

david.dible@citigatedr.co.uk

Panmure Gordon (UK) Limited

Richard Gray / Andrew Potts

+44 (20) 7886 2500

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHLIFLATLIELID
Date   Source Headline
8th Jul 20097:00 amRNSNotice of Results
30th Jun 20097:00 amRNSBlocklisting Six Monthly Return
8th May 20092:43 pmRNSResult of AGM
9th Apr 20091:19 pmRNSDirector/PDMR Shareholding
6th Apr 20097:00 amRNS2008 Annual Report and Notice of AGM
20th Mar 200911:40 amRNSNotice of AGM
20th Mar 200911:38 amRNSHolding(s) in Company
20th Mar 20097:00 amRNSHolding(s) in Company
16th Mar 20097:00 amRNSFinal Results
2nd Mar 20098:44 amRNSHolding(s) in Company
27th Feb 200911:11 amRNSNotice of Results
17th Feb 20097:00 amRNSCompletion of US Phase II Patient Enrolment
22nd Jan 20091:00 pmRNSHolding(s) in Company
22nd Jan 20091:00 pmRNSHolding(s) in Company
21st Jan 200910:43 amRNSHolding(s) in Company
19th Jan 20098:24 amRNSDirector/PDMR Shareholding
8th Jan 20097:00 amRNSClinical Update on HMPL-002
30th Dec 20087:00 amRNSBlocklisting Six Monthly Return
23rd Dec 200810:30 amRNSDrug Discovery and Development Partnership
15th Dec 20089:33 amRNSDirector/PDMR Shareholding
21st Nov 20087:00 amRNSChi-Med Expands Partnership With Lilly
30th Oct 20087:00 amRNSHutchison MediPharma Wins ACG Award
8th Oct 20087:00 amRNSBoard Change
6th Aug 20087:00 amRNSHutchison MediPharma Employee
6th Aug 20087:00 amRNSInterim Results
18th Jul 20087:00 amRNSNotice of Results
30th Jun 20088:48 amRNSBlocklisting Six Monthly Retu
10th Jun 20089:11 amRNSDirector/PDMR Shareholding
2nd Jun 20087:00 amRNSDirectorate Change
23rd May 20087:00 amRNSChi-Med increases stake in Hu
19th May 20087:00 amRNSSen French Launch
22nd Apr 20081:56 pmRNSHolding(s) in Company
9th Apr 20087:00 amRNSAnnual Report and Accounts
31st Mar 200810:31 amRNSHolding(s) in Company
19th Mar 20087:13 amRNSPreliminary Results
29th Feb 20087:00 amRNSClinical Update
28th Feb 20087:02 amRNSAddress Change Cayman Islands
28th Feb 20087:00 amRNSNotice of Results
21st Jan 20087:00 amRNSChina Healthcare division
27th Dec 20077:00 amRNSBlock Admission Return
22nd Nov 20077:03 amRNSResearch Update
20th Aug 20077:00 amRNSAgreement with Eli Lilly
9th Aug 20077:01 amRNSInterim Results
18th Jul 20077:00 amRNSNotice of Results
2nd Jul 20077:01 amRNSResearch Update
22nd Jun 20077:00 amRNSBlock Admission
18th Jun 20077:00 amRNSR&D Facility Purchase
23rd May 20077:00 amRNSResearch Update
22nd May 20077:00 amRNSDirector/PDMR Shareholding
11th May 20073:57 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.